Arundic acid: Astrocyte-modulating agent treatment of stroke treatment of neurodegeneration

Drugs of the Future

Volumn 29, Issue 5, 2004, Pages 441-448

  Sorbera, L A ^a   Castaner J ^a   Castaner R M ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMYLOID BETA PROTEIN; ARUNDIC ACID; DONEPEZIL; OCTANOIC ACID DERIVATIVE; ONO 2506PO; PROTEIN S100B; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ASTROCYTE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG INDICATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG WITHDRAWAL; HEADACHE; HUMAN; MICRODIALYSIS; MOUSE; NEUROMODULATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PASSIVE AVOIDANCE; RAT; REVIEW; STROKE;

EID: 3242892633     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2004.029.05.810151     Document Type: Review

References (38)

1. Nakai, H., Kishimoto, K. (Ono Pharmaceutical Co., Ltd.). Preparation method of optically active 2-propyl octanoate. JP 1996291106.
2. Nakai, H., Kishimoto, K. (Ono Pharmaceutical Co., Ltd.). Preparation method of optically active 2-propyloctanoic acid. JP 1996295648.
3. Hasegawa, T., Yamamoto, H. A practical synthesis of optically active (R)-2-propyloctanoic acid: Therapeutic agent for Alzheimer's disease. Bull Chem Soc Jpn 2000, 73: 423-8.
4. Yamamoto, H. (Ono Pharmaceutical Co., Ltd.). Novel intermediates and processes for the preparation of optically active octanoic acid derivs. EP 1078921, US 6333415, WO 9958513.
5. Hasegawa, T., Kawanaka, Y., Kasamatsu, E., Iguchi, Y., Yonekawa, Y., Okamoto, M., Ohta, C., Hashimoto, S., Ohuchida, S. Process development of ONO-2506: A therapeutic agent for stroke and Alzheimer's disease. Org Process Res Dev 2003, 7: 168-71.
6. Toda, N., Yamaguchi, K., Iguchi, Y. (Ono Pharmaceutical Co., Ltd.; Tokyo Kasei Kogyo Co., Ltd.). Process for the preparation of (2R)-2-propyloctanoic acid. EP 1153910, WO 0048982.
7. Hasegawa, T., Yamamoto, H. Development of new chiral auxillary derived from (S)-(-)-phenylethylamine for a synthesis of enantiopure (R)-2-propyloctanoic acid. Synthesis (Stuttgart) 2003, (8): 1181-6.
8. Tatsuta, K. (Ono Pharmaceutical Co., Ltd.). Intermediate and process for producing optically active cpd. from the intermediate. WO 0351852.
9. Prous Science Drug R&D Backgrounders: Stroke (online publication). Updated May 25, 2004.
10. Alberts, M.J. Treatment of acute ischemic stroke. J Stroke Cerebrovasc Dis 2001, 10(2, Part 2): 10-7.
11. Bravata, D.M., Ho, S.-Y., Brass, L.M., Concato, J., Scinto, J., Meehan, T.P. Long-term mortality in cerebrovascular disease. Stroke 2003, 34: 699-704.
12. Desmond, D.W., Moroney, J.T., Sano, M., Stern, Y. Incidence of dementia after ischemic stroke. Results of a longitudinal study. Stroke 2002, 33: 2254-60.
13. Broderick, J.P. William M. Feinberg Lecture: Stroke therapy in the year 2025. Burden, breakthroughs, and barriers to progress. Stroke 2004, 35: 205-11.
14. Goldstein, L.B., Adams, R., Becker, K. et al. Primary prevention of ischemic stroke. A statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 2001, 32: 280-99.
15. Murphy, S. Production of nitric oxide by glial cells: Regulation and potential roles in the CNS. Glia 2000, 29: 1-13.
16. Chao, C.C., Hu, S., Sheng, W.S., Bu, D., Bukrinsky, M.I., Peterson, P.K. Cytokine-stimulated astrocytes damage human neurons via a nitric oxide mechanism. Glia 1996, 16: 276-84.
17. Hu, J., Castets, F., Guevara, J.L., Van Eldik, L.J. S100β stimulates inducible nitric oxide synthase activity and mRNA levels in rat cortical astrocytes. J Biol Chem 1996, 271: 2543-7.
18. Matsui, T., Mori, T., Tateishi, N., Kagamiishi, Y., Satoh, S., Katsube, N., Morikawa, E., Morimoto, T., Ikuta, F., Asano, T. Astrocytic activation and delayed infarct expansion after permanent focal ischemia in rats. Part I: Enhanced astrocytic synthesis of S-100β in the periinfarct area precedes delayed infarct expansion, J Cereb Blood Flow Metab 2002, 22: 711-22.
19. Shimoda, T., Tatelshi, N., Shintaku, K., Yada, N., Katagi, J., Akiyama, T., Maekawa, H., Shinagawa, R., Kondo, K., Kondo, K. ONO-2506, a novel astrocyte modulating agent, suppresses the increase of COX-2 and iNOS mRNA expression in cultured astrocytes and ischemic brain. Soc Neurosci Abst 1998, 24(Part 1): Abst 384, 13.
20. Shinagawa, R., Tateishi, N., Shimoda, T., Shintaku, K., Yada, N., Honjo, K., Kagamiishi, Y., Kondo, K. ONO-2506 ameliorates neurodegeneration through inhibition of reduction of GLT-1 expression. Soc Neurosci Abst 1998, 24(Part 1): Abst 384.14.
21. Shinagawa, R., Tateishi, N., Shimoda, T., Maekawa, H., Yada, N., Akiyama, T., Matsuda, S., Katsube, N. Modulating effects of ONO-2506 on astrocytic activation in cultured astrocytes from rat cerebellum. Soc Neurosci Abst 1999, 25(Part 2): Abst 843.10.
22. A receptor disappearance in cultured astrocytes and ischemic brain. Soc Neurosci Abst 1999, 25(Part 2): Abst 843.11.
23. Matsuda, S., Maekawa, H., Shimoda, T., Shinagawa, R., Akiyama, T., Tateishi, N., Katsube, N. Effects of ONO-2506 on the glutathione synthesis and hydrogen peroxide toxicity. 32nd Annu Meet Soc Neurosci (Nov 2-7, Orlando) 2002, Abst 232.12.
24. Tateishi, N., Mori, T., Kagamiishi, Y., Satoh, S., Katsube, N., Morikawa, E., Morimoto, T., Matsui, T., Asano, T. Astrocytic activation and delayed infarct expansion after permanent focal ischemia in rats. Part II: Suppression of astrocytic activation by a novel agent (R)-(-)-2-propyloctanoic acid (ONO-2506) leads to mitigation of delayed infarct expansion and early improvement of neurologic deficits. J Cereb Blood Flow Metab 2002, 22: 723-34.
25. Honjo, K., Tateishi, N., Shintaku, K., Satoh, S., Katsube, N. Effects of ONO-2506 combined with thrombolytic therapy in a rat model of thrombotic focal cerebral ischemia. Soc Neurosci Abst 2001, 27: Abst 865.5.
26. Honjo, K., Tateishi, N., Shintaku, K., Shinagawa, R., Kagamiishi, Y., Katsube, N. Delayed increase of extracellular glutamate probably due to reduction of GLT-1 and GLAST following transient focal cerebral ischemia and of its inhibition by ONO-2506. Soc Neurosci Abst 1999, 25(Part 2): Abst 843.12.
27. Tateishi, N., Shintaku, K., Kitajima, S., Kohjimoto, Y., Li, X.H., Mori, T., Katsube, N. Effects of ONO-2506, an astrocyte modulating agent, on neurological symptoms after focal ischemia in cynomolgus monkeys. 32nd Annu Meet Soc Neurosci (Nov 2-7, Orlando) 2002, Abst 489.7.
28. Kato, H., Araki, T., Imai, Y., Takahashi, A., Itoyama, Y. Astroglia-mediated neuroprotection by ONO-2506 against MPTP-neurotoxicity in mice. Soc Neurosci Abst 2001, 27: Abst 199.3.
29. Yada, N., Shimoda, T., Yamashita, D., Akiyama, T., Katsube, N., Tateishi, N. Effects of ONO-2506 on amyloidgenic pathway: Implications to the treatment of Alzheimer's disease. 33rd Annu Meet Soc Neurosci (Nov 8-12, New Orleans) 2003, Abst 526.3.
30. Kishi, A., Yoshida, M., Kagamiishi, Y., Katsube, N., Mori, T., Tateishi, N. Effects of ONO-2506 on learning impairments in senescence-accelerated mouse (SAMP8). 33rd Annu Meet Soc Neurosci (Nov 8-12, New Orleans) 2003, Abst 731.2.
31. Pettigrew, L.C., Kasner, S.E., Kwiatkowski, T., Albers, G.W., Gorman, M., Grotta, J.C., Sherman, D., Funakoshi, Y. Safety and tolerability of ONO-2506 in acute ischemic stroke. Stroke 2004, 35(1): Abst P208.
32. Pettigrew, L.C., Kasner, S.E., Gorman, M., Atkinson, R.P., Dietrich, D., Ishibahi, H. ONO-2506 suppresses S-100β in ischemic stroke patients. Stroke 2004, 35(1): Abst P184.
33. Ono Pharmaceutical Annual Report 2003.
34. Asano, T., Matsui, T., Morikawa, E., Tateishi, N., Kagamiishi, Y., Satoh, S., Kondo, K. The ameliorative effect of ONO-2506 on the delayed and prolonged expansion of the infarct volume following permanent middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab 1999, 19(Suppl. 1): Abst 64.
35. Shintaku, K., Tateishi, N., Kagamiishi, Y., Sato, S., Katsumata, S., Nakayama, Y., Hayakawa, T., Katsube, N. Ameliorative effects of ONO-2506 on neurological deficits and infarction after transient MCA occlusion in rats: Study of therapeutic time window. Soc Neurosci Abst 1999, 25(Part 2): Abst 843.9.
36. Matsui, T., Tateishi, N., Kagamiishi, Y., Satoh, S., Kondo, K., Morikawa, E., Taniguchi, T., Mori, T., Asano, T. Protective effects of ONO-2506 on neurological deficits and brain infarct volume following 1 week of permanent occlusion of middle cerebral artery in rats. Soc Neurosci Abst 1998, 24(Part 1): Abst 102.7.
37. Kagamiishi, Y., Tateishi, N., Shintaku, K., Satoh, S., Katsumata, S., Shinagawa, R., Shimoda, T., Katsube, N., Kondo, K. Ameliorative effects of ONO-2506 on brain damage following the transient ischemia in rats. Soc Neurosci Abst 1998, 24(Part 1): Abst 384.11.
38. Matsuda, S., Maekawa, H., Shimoda, T., Shinagawa, R., Tateishi, N., Katsube, N. Effect of ONO-2506 on the production/consumption of glutathiones in primary rat cultured cortical astrocytes. Soc Neurosci Abst 2001, 27: Abst 715.16.